In yesterday’s Wall Street Journal, Geeta Anand and Betsy Mckay explained how the health authorities in the rapidly developing BRICS nations have agreed to work together to fight tuberculosis.
The BRICS–Brazil, Russia, India, China, and South Africa–account for about 60% of the world’s multi-drug resistant TB cases, so it is good news that they see combating MDR-TB as a policy priority.
In a journal article my team published today, we find that about one in ten TB medicines is substandard, which will significantly contribute toward drug resistant strains of TB. And we find that 63% of those substandard medicines probably come from BRICS countries. If the BRICS really want to combat MDR-TB, they should ensure that fewer fake and substandard medicines are to be found in their nations.